Literature DB >> 27812791

Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.

Charline Lasnon1,2,3, Thibault Salomon1, Cédric Desmonts1, Pascal Dô4, Youssef Oulkhouir5, Jeannick Madelaine5, Nicolas Aide6,7,8.   

Abstract

BACKGROUND: Evolutions in hardware and software PET technology, such as point spread function (PSF) reconstruction, have been shown to improve diagnostic performance, but can also lead to important device-dependent and reconstruction-dependent variations in standardized uptake values (SUVs). This may preclude the multicentre use of SUVs as a prognostic or diagnostic tool or as a biomarker of the early response to antineoplastic treatments. This study compared two SUV harmonization strategies using a newer reconstruction algorithm that improves lesion detection while maintaining comparability with older systems: (1) the use of a second reconstruction compliant with harmonization standards and (2) the use of a proprietary software tool (EQ.PET).
METHODS: PET data from 50 consecutive non-small cell lung cancer patients were reconstructed with PSF reconstruction for optimal tumor detection and an ordered subset expectation maximization (OSEM3D) reconstruction to mimic a former generation PET. An additional PSF reconstruction was performed with a 7 mm Gaussian filter (PSF7, first method), and, post-reconstruction, the EQ filter (same Gaussian filter) was applied to the PSF data (PSFEQ, second method) for harmonization purposes. The 7 mm kernel filter was chosen to comply with the European Association of Nuclear Medicine (EANM) standards. SUVs for all reconstructions were compared with regression analyses and/or Bland-Altman plots.
RESULTS: Overall, 171 lesions were analyzed: 55 lung lesions (32.2%), 87 lymph nodes (50.9%), and 29 metastases (16.9%). In these lesions, the mean PSF7/OSEM3D ratios for SUVmax and SUVpeak were 1.02 (95% CI: 0.93-1.11) and 1.04 (95% CI: 0.95-1.14), respectively. The mean PSFEQ/OSEM3D ratios for SUVmax and SUVpeak were 1.01 (95% CI: 0.91-1.11) and 1.04 (95% CI: 0.94-1.14), respectively. When comparing PSF7 and PSFEQ, Bland-Altman analysis showed that the mean PSF7/PSFEQ ratios for SUVmax and SUVpeak were 1.01 (95% CI: 0.96-1.06) and 1.01 (95% CI: 0.97-1.04), respectively.
CONCLUSION: The issue of reconstruction dependency in SUV values that hampers the comparison of data between different PET systems can be overcome using two reconstructions for harmonized quantification and optimal diagnosis or using the EQ.PET technology. Both technologies produce similar results, EQ.PET sparing reconstruction and interpretation time. Other manufacturers are encouraged to either emulate this solution or to produce a vendor-neutral approach.

Entities:  

Keywords:  18F-Fluorodeoxyglucose; Harmonization; Positron emission tomography; Quantitation; Standardized uptake value

Mesh:

Substances:

Year:  2016        PMID: 27812791     DOI: 10.1007/s12149-016-1135-2

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  20 in total

Review 1.  Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Authors:  C M Deroose; S Stroobants; Y Liu; L K Shankar; P Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

2.  Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Authors:  Benjamin Houdu; Charline Lasnon; Idlir Licaj; Guy Thomas; Pascal Do; Anne-Valerie Guizard; Cédric Desmonts; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-14       Impact factor: 9.236

Review 3.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

4.  How Often Do We Fail to Classify the Treatment Response with [18F]FDG PET/CT Acquired on Different Scanners? Data from Clinical Oncological Practice Using an Automatic Tool for SUV Harmonization.

Authors:  Maria Vittoria Mattoli; Maria Lucia Calcagni; Silvia Taralli; Luca Indovina; Bruce S Spottiswoode; Alessandro Giordano
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

5.  Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics.

Authors:  Guilherme D Kolinger; David Vállez García; Gerbrand Maria Kramer; Virginie Frings; Gerben J C Zwezerijnen; Egbert F Smit; Adrianus Johannes de Langen; Irène Buvat; Ronald Boellaard
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

6.  Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network.

Authors:  Brenda F Kurland; Lanell M Peterson; Andrew T Shields; Jean H Lee; Darrin W Byrd; Alena Novakova-Jiresova; Mark Muzi; Jennifer M Specht; David A Mankoff; Hannah M Linden; Paul E Kinahan
Journal:  J Nucl Med       Date:  2018-10-25       Impact factor: 10.057

7.  Implications of the Harmonization of [18F]FDG-PET/CT Imaging for Response Assessment of Treatment in Radiotherapy Planning.

Authors:  Elisa Jiménez-Ortega; Raquel Agüera; Ana Ureba; Marcin Balcerzyk; Amadeo Wals-Zurita; Francisco Javier García-Gómez; Antonio Leal
Journal:  Tomography       Date:  2022-04-12

8.  Digital PET compliance to EARL accreditation specifications.

Authors:  Daniëlle Koopman; Maureen Groot Koerkamp; Pieter L Jager; Hester Arkies; Siert Knollema; Cornelis H Slump; Pedro G Sanches; Jorn A van Dalen
Journal:  EJNMMI Phys       Date:  2017-01-31

Review 9.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

10.  New PET technologies - embracing progress and pushing the limits.

Authors:  Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.